Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

826 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Armed antibodies for cancer treatment: a promising tool in a changing era.
Danielli R, Patuzzo R, Ruffini PA, Maurichi A, Giovannoni L, Elia G, Neri D, Santinami M. Danielli R, et al. Among authors: elia g. Cancer Immunol Immunother. 2015 Jan;64(1):113-21. doi: 10.1007/s00262-014-1621-0. Epub 2014 Oct 15. Cancer Immunol Immunother. 2015. PMID: 25314912 Free PMC article. Review.
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C, Giovannoni L, Elia G, Neri D, Maio M, Santinami M. Danielli R, et al. Among authors: elia g. Cancer Immunol Immunother. 2015 Aug;64(8):999-1009. doi: 10.1007/s00262-015-1704-6. Epub 2015 May 14. Cancer Immunol Immunother. 2015. PMID: 25971540 Free PMC article. Clinical Trial.
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Weide B, Eigentler T, Catania C, Ascierto PA, Cascinu S, Becker JC, Hauschild A, Romanini A, Danielli R, Dummer R, Trefzer U, Elia G, Neri D, Garbe C. Weide B, et al. Among authors: elia g. Cancer Immunol Immunother. 2019 Sep;68(9):1547-1559. doi: 10.1007/s00262-019-02383-z. Epub 2019 Sep 3. Cancer Immunol Immunother. 2019. PMID: 31482307 Free PMC article. Clinical Trial.
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C. Weide B, et al. Among authors: elia g. Cancer Immunol Res. 2014 Jul;2(7):668-78. doi: 10.1158/2326-6066.CIR-13-0206. Epub 2014 Apr 4. Cancer Immunol Res. 2014. PMID: 24906352 Clinical Trial.
Limited efficacy of intratumoral IL-2 applied to large melanoma metastases.
Weide B, Eigentler TK, Elia G, Neri D, Garbe C. Weide B, et al. Among authors: elia g. Cancer Immunol Immunother. 2014 Nov;63(11):1231-2. doi: 10.1007/s00262-014-1584-1. Epub 2014 Jul 24. Cancer Immunol Immunother. 2014. PMID: 25056818 Free PMC article. No abstract available.
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.
Catania C, Maur M, Berardi R, Rocca A, Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen HD, Neri D, Cascinu S, Conte PF, Braud Fd. Catania C, et al. Among authors: elia g. Cell Adh Migr. 2015;9(1-2):14-21. doi: 10.4161/19336918.2014.983785. Cell Adh Migr. 2015. PMID: 25562532 Free PMC article. Clinical Trial.
826 results